Parkinson's disease-related proteins PINK1 and parkin repress mitochondrial antigen presentation
10.1016/j.cell.2016.05.039 · doi-reference
High resolution 16S rRNA gene Next Generation Sequencing study of brain areas associated with Alzheimer's and Parkinson's disease
10.3389/fnagi.2022.1026260 · doi-reference
Rifaximin modulates TRH and TRH-like peptide expression throughout the brain and peripheral tissues of male rats
10.1186/s12868-022-00694-z · doi-reference
Gut microbial molecules in behavioural and neurodegenerative conditions
10.1038/s41583-020-00381-0 · doi-reference
Mitochondria-targeted high-load sound-sensitive micelles for sonodynamic therapy to treat triple-negative breast cancer and inhibit metastasis
10.1016/j.msec.2021.112054 · doi-reference
Correlation between the peripheral neuropathy and levels of hs-CRP, IL-1β and IL-6 in senile Parkinson's disease patients
10.14715/cmb/2023.69.4.19 · doi-reference
Large-scale proteomic analyses of incident Parkinson's disease reveal new pathophysiological insights and potential biomarkers
10.1038/s43587-025-00818-0 · doi-reference
Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease
10.1007/s00401-024-02706-0 · doi-reference
α-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinson's disease
10.1186/s12974-022-02413-1 · doi-reference
Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial
10.1016/j.eclinm.2024.102563 · doi-reference
Gut microbiome dysbiosis across early Parkinson's disease, REM sleep behavior disorder and their first-degree relatives
10.1038/s41467-023-38248-4 · doi-reference
Mediterranean diet adherence, gut microbiota, and Alzheimer's or Parkinson's disease risk: a systematic review
10.1016/j.jns.2022.120166 · doi-reference
Disease, drugs and dysbiosis: understanding microbial signatures in metabolic disease and medical interventions
10.3390/microorganisms8091381 · doi-reference
Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome
10.1002/mds.26942 · doi-reference
Damage-associated molecular patterns in inflammatory diseases
10.4110/in.2018.18.e27 · doi-reference
Targeting cytokines, pathogen-associated molecular patterns, and damage-associated molecular patterns in sepsis via blood purification
10.3390/ijms22168882 · doi-reference
Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity
10.1073/pnas.1415174111 · doi-reference
Next-generation Nanomaterial-based phototherapeutic strategies for tumor: from NIR responsiveness to smart activation
10.1080/17435889.2025.2532357 · doi-reference
Excitatory amino acid transporter supports inflammatory macrophage responses
10.1016/j.scib.2024.03.055 · doi-reference
The role of the immune system in Parkinson's disease pathogenesis: a focus on Th17 cells - a systematic review and meta-analysis
10.1016/j.jneuroim.2024.578484 · doi-reference
α-Synuclein orchestrates Th17 responses as antigen and adjuvant in Parkinson's disease
10.1186/s12974-025-03359-w · doi-reference
Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls
10.1016/j.parkreldis.2016.08.019 · doi-reference
Interaction of RAGE with α-synuclein fibrils mediates inflammatory response of microglia
10.1016/j.celrep.2022.111401 · doi-reference
Inflammasomes in neuroinflammatory and neurodegenerative diseases
10.15252/emmm.201810248 · doi-reference
A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression
10.1111/ene.14208 · doi-reference
Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models
10.1016/j.ejphar.2022.175029 · doi-reference
Gasotransmitter hydrogen sulfide signaling in neuronal health and disease
10.1016/j.bcp.2017.11.019 · doi-reference
Lactobacillus plantarum CCFM405 against rotenone-induced Parkinson's disease mice via regulating gut microbiota and branched-chain amino acids biosynthesis
10.3390/nu15071737 · doi-reference
Tryptophan metabolism in central nervous system diseases: pathophysiology and potential therapeutic strategies
10.14336/ad.2022.0916 · doi-reference
The effects of ursodeoxycholic acid on Parkinson's disease, a mechanistic review of the recent evidence
10.1007/s11011-025-01542-9 · doi-reference
A double-blind, randomized, placebo-controlled trial of ursodeoxycholic acid (UDCA) in Parkinson's disease
10.1002/mds.29450 · doi-reference
Bile acids and neurological disease
10.1016/j.pharmthera.2022.108311 · doi-reference
The endotoxin hypothesis of Parkinson's disease
10.1002/mds.29432 · doi-reference
Paraquat exposure induces Parkinsonism by altering lipid profile and evoking neuroinflammation in the midbrain
10.1016/j.envint.2022.107512 · doi-reference
Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease
10.1016/j.nbd.2018.12.012 · doi-reference
Colonic bacterial composition in Parkinson's disease
10.1002/mds.26307 · doi-reference
Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease
10.1111/acel.13834 · doi-reference
Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design
10.1080/19490976.2023.2284247 · doi-reference
Emerging insights between gut microbiome dysbiosis and Parkinson's disease: pathogenic and clinical relevance
10.1016/j.arr.2022.101759 · doi-reference
The reciprocal interactions between microglia and T cells in Parkinson's disease: a double-edged sword
10.1186/s12974-023-02723-y · doi-reference
